The interleukin-17 family is the key group of cytokines and displays a broad spectrum of biological functions,including regulating the inflammatory cascade in various autoimmune and inflammatory diseases,such as multi...The interleukin-17 family is the key group of cytokines and displays a broad spectrum of biological functions,including regulating the inflammatory cascade in various autoimmune and inflammatory diseases,such as multiple sclerosis,neuromyelitis optica spectrum disorder,myasthenia gravis,Guillain–Barre syndrome,acute disseminated encephalomyelitis,diabetes,inflammatory skin diseases,joint inflammation,and cancer.Although the function of the interleukin-17 family has attracted increasing research attention over many years,the expression,function,and regulation mechanisms of different interleukin-17 members are complicated and still only partially understood.Currently,the interleukin-17A pathway is considered a critical therapeutic target for numerous immune and chronic inflammatory diseases,with several monoclonal antibodies against interleukin-17A having been successfully used in clinical practice.Whether other interleukin-17 members have the potential to be targeted in other diseases is still debated.This review first summarizes the recent advancements in understanding the physicochemical properties,physiological functions,cellular origins,and downstream signaling pathways of different members and corresponding receptors of the interleukin-17 family.Subsequently,the function of interleukin-17 in various immune diseases is discussed,and the important role of interleukin-17 in the pathological process of immune diseases is demonstrated from multiple perspectives.Then,the current status of targeted interleukin-17 therapy is summarized,and the effectiveness and safety of targeted interleukin-17 therapy are analyzed.Finally,the clinical application prospects of targeting the interleukin-17 pathway are discussed.展开更多
目的观察芪参还五胶囊对冠心病患者心功能的改善及对外周血Th17/Treg平衡的影响。方法选择于医院治疗的110例冠心病患者,2021年1月—2022年6月为病例入组时间,分组方式为随机数字表法,西医组55例,给予西医基础治疗;芪参还五胶囊组55例,...目的观察芪参还五胶囊对冠心病患者心功能的改善及对外周血Th17/Treg平衡的影响。方法选择于医院治疗的110例冠心病患者,2021年1月—2022年6月为病例入组时间,分组方式为随机数字表法,西医组55例,给予西医基础治疗;芪参还五胶囊组55例,在西医基础治疗同时给予患者芪参还五胶囊治疗。治疗前、后检测两组患者Th17/Treg细胞比例、血红素加氧酶1(HO-1)、一氧化氮(NO)、白细胞介素-35(IL-35)、脂联素(APN)、白细胞介素-17A(IL-17A)、血管性血友病因子(vWF)、脂蛋白相关磷脂酶A2(Lp-PLA2)水平,检测患者冠状动脉微循环指标:冠状动脉血流储备(CFR)、血流量(Qmean)、平均循环抵抗指数(IMR),检测患者心肌耗氧量、左室射血分数(LVEF)、连续窦性R-R间期标准差(SDNN)、24 h QT离散度(QTd),给予患者动则喘息、胸闷气短、心胸隐痛、胸痛反复发作、倦怠懒言、面色㿠白评价,比较西医组及芪参还五胶囊组临床疗效。结果芪参还五胶囊组患者Th17/Treg、IL-17A含量较西医组明显降低(P<0.05),芪参还五胶囊组HO-1、IL-35含量较西医组升高(P<0.005);芪参还五胶囊组患者Lp-PLA2、vWF含量较西医组明显降低(P<0.05),芪参还五胶囊组患者NO、APN含量较西医组升高(P<0.05);芪参还五胶囊组CFR、Qmean较西医组明显升高(P<0.05),芪参还五胶囊组IMR较西医组明显降低(P<0.05);芪参还五胶囊组患者心肌耗氧量、QTd较西医组明显降低(P<0.05),芪参还五胶囊组LVEF、SDNN较西医组升高(P<0.05);芪参还五胶囊组患者心悸易汗、动则喘息、胸闷气短、心胸隐痛、胸痛反复发作、倦怠懒言、面色㿠白评分较西医组明显降低(P<0.05),芪参还五胶囊组总有效率为98.18%,西医组总有效率为83.64%,芪参还五胶囊组患者总有效率高于西医组(P<0.05)。结论芪参还五胶囊治疗冠心病患者,可调节机体Th17/Treg平衡,抑制机体炎症,减少血管内皮损伤,改善患者心功能、冠状动脉微循环及心电图指标,提升患者临床疗效。展开更多
基金supported by the National Natural Science Foundational of China(Key Program),No.U24A20692(to CJZ)the National Natural Science Foundational of China,Nos.82101414(to MLJ),82371355(to CJZ)+4 种基金the National Natural Science Foundational of China for Excellent Young Scholars,No.82022019(to CJZ)Sichuan Special Fund for Distinguished Young Scholars,No.24NSFJQ0052(to CJZ)The Innovation and Entrepreneurial Team of Sichuan Tianfu Emei Program,No.CZ2024018(to CJZ)Funding for Distinguished Young Scholars of Sichuan Provincial People’s Hospital,No.30420230005(to CJZ)Funding for Distinguished Young Scholars of University of Electronic Science and Technology of China,No.A1098531023601381(to CJZ)。
文摘The interleukin-17 family is the key group of cytokines and displays a broad spectrum of biological functions,including regulating the inflammatory cascade in various autoimmune and inflammatory diseases,such as multiple sclerosis,neuromyelitis optica spectrum disorder,myasthenia gravis,Guillain–Barre syndrome,acute disseminated encephalomyelitis,diabetes,inflammatory skin diseases,joint inflammation,and cancer.Although the function of the interleukin-17 family has attracted increasing research attention over many years,the expression,function,and regulation mechanisms of different interleukin-17 members are complicated and still only partially understood.Currently,the interleukin-17A pathway is considered a critical therapeutic target for numerous immune and chronic inflammatory diseases,with several monoclonal antibodies against interleukin-17A having been successfully used in clinical practice.Whether other interleukin-17 members have the potential to be targeted in other diseases is still debated.This review first summarizes the recent advancements in understanding the physicochemical properties,physiological functions,cellular origins,and downstream signaling pathways of different members and corresponding receptors of the interleukin-17 family.Subsequently,the function of interleukin-17 in various immune diseases is discussed,and the important role of interleukin-17 in the pathological process of immune diseases is demonstrated from multiple perspectives.Then,the current status of targeted interleukin-17 therapy is summarized,and the effectiveness and safety of targeted interleukin-17 therapy are analyzed.Finally,the clinical application prospects of targeting the interleukin-17 pathway are discussed.
文摘目的观察芪参还五胶囊对冠心病患者心功能的改善及对外周血Th17/Treg平衡的影响。方法选择于医院治疗的110例冠心病患者,2021年1月—2022年6月为病例入组时间,分组方式为随机数字表法,西医组55例,给予西医基础治疗;芪参还五胶囊组55例,在西医基础治疗同时给予患者芪参还五胶囊治疗。治疗前、后检测两组患者Th17/Treg细胞比例、血红素加氧酶1(HO-1)、一氧化氮(NO)、白细胞介素-35(IL-35)、脂联素(APN)、白细胞介素-17A(IL-17A)、血管性血友病因子(vWF)、脂蛋白相关磷脂酶A2(Lp-PLA2)水平,检测患者冠状动脉微循环指标:冠状动脉血流储备(CFR)、血流量(Qmean)、平均循环抵抗指数(IMR),检测患者心肌耗氧量、左室射血分数(LVEF)、连续窦性R-R间期标准差(SDNN)、24 h QT离散度(QTd),给予患者动则喘息、胸闷气短、心胸隐痛、胸痛反复发作、倦怠懒言、面色㿠白评价,比较西医组及芪参还五胶囊组临床疗效。结果芪参还五胶囊组患者Th17/Treg、IL-17A含量较西医组明显降低(P<0.05),芪参还五胶囊组HO-1、IL-35含量较西医组升高(P<0.005);芪参还五胶囊组患者Lp-PLA2、vWF含量较西医组明显降低(P<0.05),芪参还五胶囊组患者NO、APN含量较西医组升高(P<0.05);芪参还五胶囊组CFR、Qmean较西医组明显升高(P<0.05),芪参还五胶囊组IMR较西医组明显降低(P<0.05);芪参还五胶囊组患者心肌耗氧量、QTd较西医组明显降低(P<0.05),芪参还五胶囊组LVEF、SDNN较西医组升高(P<0.05);芪参还五胶囊组患者心悸易汗、动则喘息、胸闷气短、心胸隐痛、胸痛反复发作、倦怠懒言、面色㿠白评分较西医组明显降低(P<0.05),芪参还五胶囊组总有效率为98.18%,西医组总有效率为83.64%,芪参还五胶囊组患者总有效率高于西医组(P<0.05)。结论芪参还五胶囊治疗冠心病患者,可调节机体Th17/Treg平衡,抑制机体炎症,减少血管内皮损伤,改善患者心功能、冠状动脉微循环及心电图指标,提升患者临床疗效。
